# The Effect of Lixisenatide on the Effect of Pituitary Hormones

> **NCT05804513** · PHASE4 · UNKNOWN · sponsor: **University of Tartu** · enrollment: 10 (estimated)

## Conditions studied

- Healthy
- Type 1 Diabetes

## Interventions

- **DRUG:** Placebo
- **DRUG:** Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector

## Key facts

- **NCT ID:** NCT05804513
- **Lead sponsor:** University of Tartu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-17
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804513, "The Effect of Lixisenatide on the Effect of Pituitary Hormones". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05804513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*